natgillin/translations-raw huggingface dataset:
The system of claim 4, further comprising an additional sensor configured to monitor current provided to the solenoid of the flush valve. The system of claim 3, further comprising an additional sensor configured to monitor fluid pressure within the flow passage to determine if a blockage is present in an outflow conduit downstream of the fluid outlet. 
Sustav u skladu s patentnim zahtjevom 2, naznačen time što dodatno sadrži dodatni senzor, konfiguriran za praćenje struje kroz zavojnicu (28) elektromagnetskog ventila (10), ili konfiguriran za praćenje tlaka tekućine u putu protoka radi određivanja ima li blokade u izlaznom cjevovodu nizvodno od izlaza tekućine (20).
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is polycythemia vera (PV). 
Spoj ili sol prema zahtjevu 69 naznačen time da navedeni mijeloproliferativni poremećaj (MPD) je policitemija vera (PV).
the Eosin-Y is present in amounts sufficient to result in concentrations of about 10 µM to about 50 µM under staining conditions. 
Eozin-Y je prisutno u dovoljnoj količini da se dobiju koncentracije od oko 10 uM do oko 50 uM u uvjetima bojenja.
The crystalline structure as defined in Claim 1 having the formula Ia 
Kristalna struktura kako je definirano u zahtjevu 1 naznačena time da ima formulu Ia [image]
the reaction of a compound of formula (IV) in the presence of a compound of formula (V); wherein R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, A, m, n and p are as defined in claim 1 and X in step a) is halogen or triflate and in step b) is halogen. 
reakciju spoja formule (IV) u prisutnosti spoja formule (V); pri čemu su R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, A, m, n i p definirani patentnim zahtjevom 1, dok je X u koraku a) halogen ili triflat, a u koraku b) je halogen.
The combined EtOAc fractions were washed with brine and dried over Na2SO4. 
Spojene EtOAc frakcije su isprane fiziološkom otopinom i sušene preko Na»SOy.
The pharmaceutical composition according to claim 1, wherein the composition provides equal or superior therapeutic efficacy to the commercially available daily injectable dosage forms, with reduced incidence of side effects or with reduced severity of side effects at the local or systemic level; or wherein the composition provides prolonged release or prolonged action of glatiramer in a subject as compared to a substantially similar dose of an immediate release formulation of glatiramer acetate. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time, da pripravak osigurava jednaku ili superiornu terapeutske učinkovitosti na komercijalno dostupne dnevne oblike doziranja za injekcije glatiramer acetata, s reduciranom učestalošću i/ili ozbiljnosti nuspojava na lokalnoj 1 / ili sustavnoj razini; i pri čemu pripravak dalje osigurava produljeno oslobađanje 1li produženo djelovanje glatiramera kod pojedinca u usporedbi sa supstancijalno sličnom dozom formulacije za trenutno otpuštanje glatiramer acetata.
In particular, the peripheral region 24 of said breathable and waterproof membrane element 22 is sandwiched between the skirt 20 and the lower layer 18. 
Posebice, rubno područje 24 navedenog prozračnog i vodootpornog membranskog elementa 22 se nalazi između oplate 201 donjeg sloja 18.
Six concentrations are tested. 
Testirano je šest koncentracija.
The process according to any one of the preceding claims, characterized in that from 20 to 70 wt%, preferably from 36 to 68 wt%, more preferably from 40 to 60 wt%, e.g. 50 wt% of the at least one mineral material particles have a particle size of < 2 µm after step c). 
. Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da od 20 do 70 % tež., poželjno od 36 do 68 % tež., poželjnije od 40 do 60 % tež., npr. 50 % tež. čestica najmanje jednog mineralnog materijala imaju veličinu čestica od < 2 um nakon koraka c).
The groups A, D, E, G, R30, R40, R50 and R60 in the compounds of the formulae Ia, Ib and IIc are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group which is later converted into the final group. 
R gdje su skupine A, D, E, G, R'", R*", R", R* i R u spojevima formula II i III definirane kao u spojevima formule I, gdje uz to funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, a skupina J u spoju formule II je HO-, (C,-C,)-alkil-O- ili halogen.
wherein: X is a signal peptide or wherein the signal peptide is a protein selected from the group consisting of F1gI, NadA and pelB. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je X signalni peptid proteina kojeg se bira iz skupine koju čine Flgl, NadA i pelB.
In still other embodiments, the TNF ligand is selected from any one or more of 4-1BBL, OX40L, CD70, LIGHT, and CD30L. 
'T-stanica prema zahtjevu 16, naznačena time da je navedeni drugi rekombinantni ko-stimulacijski ligand odabran iz skupine koju čine OX40L, CD70, LIGHT, CD30L i CD86.
A method of preparing a solution for intravenous infusion, comprising: providing a vial that comprises lyophilised ecteinascidin and a disaccharide, adding water to form a reconstituted solution, and diluting said reconstituted solution with an aqueous system. 
Postupak za pripremu otopine za intravenoznu infuziju, naznačen time što obuhvaća: omogućuje uporabu ampule koja sadrži liofilizirani ekteinascidin i disaharid, dodavanje vode kako bi nastala rekonstruirana otopina i razrjeđivanje navedene rekonstruirane otopine sa vodenim sustavom.
Such value is obtained when the divider formed by resistors 76, 77 outputs a nominal voltage equal to half of the supply voltage. 
Ova vrijednost se postiže kada djelitelj sastavljen iz otpornika 76, 77 daje napon jednak polovini napona napajanja.
For example, FIG. 5 illustrates the following components. 
Tako, na primjer, slika 5 prikazuje slijedeće komponente.
Wind system according to claim 4, characterised in that said winding and unwinding system (22) comprises for each of said ropes (4) at least two pairs of faced tracks pushed by pistons, inside each one of which said rope (4) is inserted. 
Vjetreni sustav (1) prema zahtjevu 1, naznačen time da je spomenuta užad (4) opremljena jednim automatskim sustavom za spajanje i razdvajanje, preko kojega se ta užad (4) može reverzibilno spojiti i odvojiti od spomenutog zmaja (2).
The lipid particle of any of claims 7 to 9 wherein the particle further comprises a therapeutic agent, preferably wherein the therapeutic agent is a nucleic acid, preferably wherein the nucleic acid is an interfering RNA, preferably wherein the interfering RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate dsRNA, a small hairpin RNA (shRNA), and mixtures thereof. 
Čestica lipida u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačena time, da čestica nadalje sadrži terapijsko sredstvo, pri čemu je terapijsko sredstvo poželjno nukleinska kiselina, pri čemu je nukleinska kiselina poželjno mRNK ili interferirajuća RNK, pri čemu je interferirajuća RNK poželjno odabrana iz skupine koja se sastoji od male interferirajuće RNK (siRNK), asimetrične interferirajuće RNK (aiRNK), mikroRNK (miRNK), Dicer-supstrata dsRNK, malene RNK-a (sShRNK) i njihovih smjesa.
is pyridinyl, pyrimidinyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C1-C4 alkyl; 
je piridinil, pirimidinil, oksazolil ili tiazolil, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen i C1-C4 alkil.
Into this solution was added aqueous H3PO4 solution (0.5 M, 95 mL). 
U ovu otopinu je dodana vodena H3PO, otopina (0.5 M, 95 mL).
Container assembly (300) comprising 
Sklop (300) posude sadrži:
Preferably, said administration by continuous infusion of the CD19xCD3 bispecific single chain antibody (i.e. one treatment cycle) is to be repeated at least two, three times, four, five, six, seven, eight, nine or even up to ten times, after determination of a MRD negative status, for consolidation. 
Konstrukt za uporabu prema zahtjevu 8, naznačen time što se nakon određivanja negativnog statusa MRD-a navedeno davanje ponavlja najmanje dva, tri, četiri, pet, šest, sedam, osam, devet i deset puta.
said dose form provides sustained release of said active ingredient; and 
navedeni dozni oblik omogućava odgođeno oslobađanje navedenog djelotvornog sastojka; i
a charge variant of the polypeptide. 
varijanta naboja polipeptida.
The explosion proof and environment protective oil refueling equipment of Claim 10, characterized in that said skid is fixed onto an anti-collision foundation to form a ground oil refueling equipment, or it is attached to the elevating mechanism of refueling machine and the tunnel base of tank pool to form an underground oil refueling equipment, or it is attached with the fixed platform of a vehicle or ship hull to form a vehicle/ship mounted oil refueling equipments, or being fixed on the inner bottom plate of a container to form a container type oil refueling equipment. 
Oprema za nadolijevanje nafte koja je otporna na eksploziju i štiti okoliš prema zahtjevu 3, naznačena time da je navedeni klizač (400) učvršćen na protu-kolizijski temelj da se dobije nadzemna oprema za nadolijevanje nafte, ili povezan s podiznim mehanizmom stroja za nadolijevanje (X) i bazom tunela bazena spremnika da se dobije podzemna oprema za nadolijevanje nafte, ili je povezan sa nepomičnom platformom tijela vozila ili oplatom broda da se dobije oprema za nadolijevanje nafte postavljena na vozilo/brod, ili je učvršćen na donju unutrašnju ploču spremnika da se dobije tip opreme za nadolijevanje nafte koji je postavljen na spremnik.
A method of inhibiting in a subject the onset or progression of a condition associated with vasopressin receptor activity, which comprises administering to the subject a prophylactically-effective dose of a compound of Formula I as defined in claim 1, wherein said condition is selected from inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, diabetic nephropathy, hyponatremia, cerebral edema, cerebral ischemia, stroke, thrombosis, water retention, aggression, obsessive-compulsive disorders, dysmenorrhea, nephrotic syndrome, anxiety and central nervous injuries. 
Spoj Formule I, kao što je definirano u Zahtjevu 1, za upotrebu kod osobe kao inhibitora kod napadaja ili progresije kod stanja povezanog s aktivnošću receptora za vazopresin, naznačen time, da je spomenuto stanje izabrano od poremećaja unutarnjeg uha, hipertenzije, kongestivnog zatajenja srca, srčane insuficijencije, koronarnog vazospazma, srčane ishemije, ciroze jetre, bubrežnog vazospazma, zatajenja bubrega, dijabetesne nefropatije, hiponatrijemije, cerebralnog edema, cerebralne ishemije, kapi, tromboze, zadržavanja vode, agresije, opsesivnogkompulsivnih poremećaja, dismenoreje, nefrotičkog sindroma, anksiozosti i ozljeda središnjeg živčanog sustava.
For testing the effect of compounds for possible antagonism, capsaicin was used at the EC80 concentration which was 0.05 µM for the rat TRPV1 receptor, and 0.1 µM for the human and guinea pig. 
Za ispitivanje učinka spojeva u smislu mogućeg antagonizma, kapsaicin je upotrijebljen u koncentraciji ECgo, koja je bila 0,05 pM za TRPVI receptor štakora, 1 0,1 M za humani i recepetor zamorca.
A method as claimed in claim 4 wherein said CTCs are derived from a solid tumor such as an ovarian, prostate or breast cancer tumor. 
Postupak za koji se traži zaštita u jednom od patentnih zahtjeva 21 do 24, pri čemu je najmanje jedna cirkulirajuća stanica tumora izvedena iz čvrstog tumora kao što je tumor jajnika, prostate, ili tumor karcinoma dojke.
The labeled compounds of the present invention bind to the RUP25 receptor. 
Označeni spojevi prikazanog izuma vežu se na RUP25 receptor.
a rare vasculitide, such as Behçet's disease. A compound for use according to claim 36, wherein the treatment is treatment of: rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; or ankylosing spondylitis. 
Spoj za uporabu prema zahtjevu 36, naznačen time, da se kod liječenja radi o liječenju sljedećih stanja: reumatoidni artritis; psorijaza; psorijatički artritis; kronična opstrukcijska plućna bolest (COPD); astma; ateroskleroza; upalna bolest crijeva; ili ankilozni spondilitis.
The compound according to claim 2 wherein A is selected from the group consisting of 
Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran iz skupine koja se sastoji od
Expression of gp130 is ubiquitous, in contrast, cellular distribution of IL-6R is limited and is predominantly confined to hepatocytes and leukocyte subpopulations. 
Ekspresija gp130 je izdašna, a nasuprot tome, stanična distribucija IL-6R je limitirana 1 pretežito ograničena na subpopulacije hepatocita 1 leukocita.
The method according to claim 5, wherein the disease presenting cellular aging is selected from the group consisting of tumors, cancers, inflammation of tissues and diseases related to the skin. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se bolesti kod kojih dolazi do staničnog starenja bira iz skupine koju čine tumori, razni oblici raka, upala tkiva i bolesti vezane uz kožu.
an exchange surface at the distal end of the first lumen comprising a plurality of pores enabling fluid exchange between the catheter and an environment surrounding the catheter; 
Sustav katetera za izmjenu tekućine prema patentnom zahtjevu 1, koji dalje sadrži površinu za izmjenu koja je raspoređena na distalnom kraju vanjskog lumena.
Recombinant FSH according to any preceding claim having a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 8 mol/mol to 14 mol/mol. Recombinant FSH according to any preceding claim expressed in a human cell line. A pharmaceutical composition comprising rFSH according to any preceding claim. 
Farmaceutski pripravak koji sadrži rFSH uključujući 02,3-sialilaciju i 02,6-sialilaciju gdje 60% ili više od ukupne sialilacije je 02,3-sialilacija i od 5 do 40% od ukupne sialilacije je 02,6-sialilacija; te ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 16 mol/mol.
With respect to the initial solids content of step b), it is thus preferred that the final solids content of the aqueous suspension after step d) is at least 1 wt %, preferably at least 2 wt %, more preferably at least 3 wt % higher than the initial solids content of the aqueous suspension obtained in step b). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je konačni udio krutih tvari u vodenoj suspenziji nakon koraka d) najmanje 1 % tež., poželjno najmanje 2 % tež., poželjnije najmanje 3 % tež. veći nego početni udio krutih tvari u vodenoj suspenziji dobivenoj u koraku b).
and wherein the benzyl group is optionally substituted with 1, 2 or 3 RA or R1 substituents, provided that the compound of Formula IIA, formula IIB or formula IIC is other than 
-C(-N=N-)(CF3), i gdje benzil grupa je po izboru supstituirana sa 1, 2 ili 3 RA ili R1 supstituenta, pod uvjetom da Spoj formule IIA, formule IIB ili formule IIC je različit od
The polypeptide according to any one of claims 1 to 8, or produced according to the process of claim 11, for use in the prevention, treatment or amelioration of a disease selected from the group consisting of a proliferative disease, an inflammatory disease, an infectious disease and an autoimmune disease. 
Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 8, ili proizveden u skladu s postupkom prema patentnom zahtjevu 11, naznačen time što je za uporabu za prevenciju, liječenje ili ublažavanje bolesti odabrane iz skupino koja se sastoji od proliferativne bolesti, upalne bolesti, zarazne bolesti i autoimune bolesti.
has a heavy chain that comprises the amino acid sequence of SEQ ID NO:25 and a light chain that comprises the amino acid sequence of SEQ ID NO:26. 
ima teški lanac koji ima aminokiselinski slijed sa SEQ ID NO:25 i laki lanac koji ima aminokiselinski slijed sa SEQ ID NO:26.
A buprenorphine solvent may also be included in the transdermal delivery systems of the present invention. 
Otapalo buprenorfina se može također uključiti u sustave za transdermalno izdavanje iz ovog izuma.
A compound according to claim 1 wherein R1 is RC, which is optionally substituted with one or more R7 groups. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R! je RÅ, koji je izborno supstituiran s jednom ili više skupina R'.
"alkoxy" means an alkyl-O- group in which the alkyl group is as defined above, particularly comprising 1 to 12 carbon atoms; 
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a ogobito sadrži 1 do 12 atoma ugljika;
The method of claim 1, wherein the therapeutically effective amount of the sartan is administered daily for a treatment period comprising a plurality of days, and the daily dosage amount administered to the cat is varied over the treatment period. 
Sartan za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se farmaceutski sastav primjenjuje na mački u terapeutski djelotvornoj količini jednom na dan.
The pneumatic precision seed drill in accordance with claim 1 wherein the pair of separating plates (4, 5) are fitted with an interior mechanism (34, 35) for interrupting the air flow. 
Srce za sijanje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time da je par ploča (4,5) za odvajanje opremljen sa unutrašnjim mehanizmom (34) za prekidanje toka zraka.
In a first aspect, the present invention provides compounds of formula (I) in free or salt form, wherein 
U prvom obliku, predloženi izum osigurava spojeve formule (1), R? 1
or phenyl, substituted in ortho-position relative to the isoquinolinone or quinazolinone by R3O- and substituted in para- or meta-position by a substituent selected from methyl, chloro, C1-C7-alkyl-carbonyl- or C1-C7-alkoxy-carbonyl-; 
fenil, supstituiran na orto-poziciji u odnosu na izokinolinon ili kinazolinon s R3O- i supstituiran na para-poziciji ili meta-poziciji sa supstituentom odabranim od sljedećih: metil, kloro, C1-C7-alkil-, karbonil- ili C1-C7-alkoksi-karbonil-;
Such a dispenser and container are described in detail in NL 1019054 and in PCT/NL99/00454, both in the name of the Applicant. 
Takav djelitelj i spremnik su pobliže opisani u NL 1019054 i u WO 00/039 44 A1, oba u ime Kandidata.
Suitably, the liquid pharmaceutical composition comprises a buffer system (suitably a histidine buffer system comprising a histidine buffering agent) at a concentration of from about 2 to about 50 mM. 
Vodeni farmaceutski pripravak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da pripravak sadrži histidinsko pufersko sredstvo (ili histidinski puferski sustav) u koncentraciji od 2 do 50 mM.
the core is openable; a toy figure is disposed inside the core; and the play objects hidden under the wrappers bear a play relationship with the toy figure inside the core. 
jezgru (14) se može otvoriti; u jezgri (14) se nalazi igraći lik; i igraći objekti (30, 50, 66, 76, 86, 96) skriveni ispod omotača (20, 40) imaju igraći odnos s igraćim likom u jezgri.
contacting an indicator composition with: a test anti-tumor agent alone, an anti-PSMA antibody of claims 1 or 2 alone, and 
(a) samo s testnim protutumorskim sredstvom, (b) samo s anti-PSMA protutijelom iz patentnog zahtjeva 1 ili 2,1
The barley plant, or part thereof, according to claim 1, wherein the mutation in the gene encoding MMT is a G to A mutation of base 3076 of SEQ ID NO:3 or a G to A mutation of base 1462 of SEQ ID NO:16. 
Biljka ječma, ili njezin dio, sukladno bilo kojem od zahtjeva 6 do 7, pri čemu je mutacija genetskog koda MMT G->A mutacija baznog br. 307612 SEQ ID NO:3 ili G>A mutacija baznog br.. 1462 iz SEQ ID NO:16.
The compound for use of claim 1, wherein the disease or disorder is lymphoma. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika.
The method of inducing an immune response against E. coli comprising administering to a subject a vaccine in accordance with any one of embodiments 16-18, 28-30, 42-44, and 54-56 or an immunogenic composition in accordance with any one of embodiments 57-61. 
Cjepivo u skladu s bilo kojim od zahtjeva 14-16, ili imunogenski sastav u skladu sa bilo kojim od zahtjeva 17-20 za upotrebu u postupku induciranja imunog odziva protiv E. coli, pri čemu postupak sadrži administriranje spomenutog cjepiva ili imunogenskog sastava subjektu.
The isolated nucleic acid of Claim 9, wherein said nucleic acid is present in a vector. 
Izolirana nukleinska kiselina prema zahtjevu 9, naznačena time da se navedena nukleinska kiselina nalazi u vektoru.
Magnesium Stearate 10.0 and the third layer comprises 150 ± 8.0 mg of microcrystalline cellulose or lactose monohydrate, or a mixture thereof. 
Žal iMagnezijev stearat eeej a treći sloj sadrži 150 + 8.0 mg mikrokristalne celloze ili laktoza monohidrata, ili njihove miketor 17.
This can mean that the filling medium is evaporated from the groove structures 4 by an increase in temperature. 
To može značiti da se punilo ispari iz brazdastih struktura 4 pomoću povišene temperature.
A method of controlling grasses and weeds in crops of useful plants, which comprises applying a herbicidally effective amount of a compound of Formula (I) according to claim 1, or of a composition comprising such a compound, to the plants or to the locus thereof. 
Postupak suzbijanja trava i korova u prinosima usjeva korisnih biljaka, naznačen time, da obuhvaća primjenu herbicidno učinkovite količine spoja formule (I) koji je određen u bilo kojem zahtjevu 1 do 22, ili sastava koji sadrži takav spoj, na biljke ili na mjesto usjeva.
Process for synthesising deoxybiotinyl hexamethylenediamine-DOTA which involves reacting biotinyl hexamethylenediamine with tri- t -butyl-DOTA in the presence of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, as the condensing agent, and triethylamine, as the base. 
Postupak sinteze deoksibiotinil heksametilendiamin-DOTA, naznačen time, da uključuje reakciju biotinil heksametilendiamina s tri-f-butil-DOTA u nazočnosti benzotriazol-1-il-oksitripirolidinfosfonij heksafluorotostata, kao agensa kondenzata i trietilamina kao lužine.
The polypeptide of claim 1 wherein at least one of the soluble TNF superfamily cytokine domains is a soluble TRAIL domain with an N-terminal sequence which starts at amino acid Gln120, Arg121, or Val122 of human TRAIL (SEQ ID NO: 10), and the Arg121 is optionally replaced by a neutral amino acid of serine or glycine. 
Polipeptid prema bilo kojem od zahtjeva 1-2 pri kojem je najmanje jedna od topljivih citokinskih domena iz TNF obitelji, naročito najmanje jedna topljiva citokinska domena TNF obitelji (iii) i (v), topljiva TRAIL domena s N-terminalnim slijedom koji počinje između amino kiseline Gln120 1 Val122 od humane TRAIL i pri čemu Arg121 može biti zamijenjena neutralnom aminokiselinom, primjerice Ser ili Gly.
treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of the compound or enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof; 
liječenju raka u bolesnika, koje obuhvaća korake: odabir bolesnika s neprirodnom aktivnošću signalnog puta Stat3; i primjenu terapijski učinkovite količine spoja formule VIII bolesniku;
The composition according to embodiment 1 or 11, wherein said biologically active polypeptide is selected from the group consisting of insulin, protein YY (PYY), IFN-a, IFN-B, and IFN-Y. 
Pripravak prema zahtjevu 1 ili 11, naznačen time da je navedeni biološki aktivni polipeptid odabran iz skupine koja se sastoji od inzulina, proteina YY (PYY), IFN-qa, IFN-f, i IFN-y.
Or the entire receiver/bottle 30/20 could remain in the fixed upright position. 
Ili cio sklop nosač 30/boca 20 može ostati u fiksiranom vertikalnom položaju.